Literature DB >> 35188065

Different isoforms of growth hormone (20 kD-GH and 22 kD-GH) shows different biological activities in mesenchymal stem cell (MSC).

Wei V Zheng1, Yaqin Li2, Yanwei Xu1, Donghui Lu3, Tao Zhou1, Dezhi Li1, Xianyi Cheng1,4, Yu Xiong1,4, Shaobin Wang5, Zaizhong Chen1,4.   

Abstract

There are two main types of growth hormone (GH) in the circulatory system. One is 22 kD-GH, which is the predominant isoform in the circulating system, 90% GH is present as a 22 kD protein, and 10% of GH is present as a 20 kD protein. Amino acid sequences are identical between 20 kD-GH and 22 kD-GH protein, except that 20 kD-GH lacks 15 amino acid residues 32 to 46. Studies have shown that GH has many important biological effects on mesenchymal stem cells (MSCs). However, so far, the cellular characteristics of the two types of GH have not been studied in BM-MSCs. Furthermore, the biological activity of 20 kD-GH has not been explored in BM-MSCs. For this, in the current work, BM-MSCs were used as in vitro cell model. We have carried out the current research using a series of experimental techniques (such as Western-blot and indirect immunofluorescence). Firstly, we explored the cell behavior of two types of GH in the Bm-MSC model and found that they showed different biological characteristics; Secondly, we investigated the biological characteristics of 20 kD-GH and 22 kD-GH, and results showed that 22 kD-GH and 20 kD-GH exhibited different signaling profiles; Thirdly, we found that the 20 kD-GH and 22 kD-GH Gexhibited different regulatory effects on the osteogenic differentiation of BM-MSCs. The current research lays a solid foundation for further studies on the regulatory effects of GH on MSCs.

Entities:  

Keywords:  20kD-GH; 22kD-GH; internalization; osteogenic differentiation; signaling profile

Mesh:

Substances:

Year:  2022        PMID: 35188065      PMCID: PMC9037433          DOI: 10.1080/15384101.2022.2035491

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   5.173


  28 in total

Review 1.  Future perspective of induced pluripotent stem cells for diagnosis, drug screening and treatment of human diseases.

Authors:  Qizhou Lian; Yenyen Chow; Miguel Angel Esteban; Duanqing Pei; Hung-Fat Tse
Journal:  Thromb Haemost       Date:  2010-06-10       Impact factor: 5.249

2.  Growth hormone synergizes with BMP9 in osteogenic differentiation by activating the JAK/STAT/IGF1 pathway in murine multilineage cells.

Authors:  Enyi Huang; Gaohui Zhu; Wei Jiang; Ke Yang; Yanhong Gao; Qing Luo; Jian-Li Gao; Stephanie H Kim; Xing Liu; Mi Li; Qiong Shi; Ning Hu; Linyuan Wang; Hong Liu; Jing Cui; Wenwen Zhang; Ruidong Li; Xiang Chen; Yu-Han Kong; Jiye Zhang; Jinhua Wang; Jikun Shen; Yang Bi; Joseph Statz; Bai-Cheng He; Jinyong Luo; Huicong Wang; Feng Xiong; Hue H Luu; Rex C Haydon; Li Yang; Tong-Chuan He
Journal:  J Bone Miner Res       Date:  2012-07       Impact factor: 6.741

3.  Specific monoclonal antibodies and ultrasensitive immunoassays for 20K and 22K human growth hormone.

Authors:  Zida Wu; Emral Devany; Giovanna Balarini; Riia Junnila; Martin Bidlingmaier; Christian J Strasburger
Journal:  Growth Horm IGF Res       Date:  2010-03-20       Impact factor: 2.372

4.  Functional, molecular and proteomic characterisation of bone marrow mesenchymal stem cells in rheumatoid arthritis.

Authors:  M-C Kastrinaki; P Sidiropoulos; S Roche; J Ringe; S Lehmann; H Kritikos; V-M Vlahava; B Delorme; G D Eliopoulos; C Jorgensen; P Charbord; T Häupl; D T Boumpas; H A Papadaki
Journal:  Ann Rheum Dis       Date:  2007-10-05       Impact factor: 19.103

5.  The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities.

Authors:  Adriana López Ponte; Emeline Marais; Nathalie Gallay; Alain Langonné; Bruno Delorme; Olivier Hérault; Pierre Charbord; Jorge Domenech
Journal:  Stem Cells       Date:  2007-03-29       Impact factor: 6.277

6.  An agonist-induced conformational change in the growth hormone receptor determines the choice of signalling pathway.

Authors:  Scott W Rowlinson; Hideo Yoshizato; Johanna L Barclay; Andrew J Brooks; Stuart N Behncken; Linda M Kerr; Kirstin Millard; Kathryn Palethorpe; Katherine Nielsen; Jodie Clyde-Smith; John F Hancock; Michael J Waters
Journal:  Nat Cell Biol       Date:  2008-05-18       Impact factor: 28.824

7.  GH prevents adipogenic differentiation of mesenchymal stromal stem cells derived from human trabecular bone via canonical Wnt signaling.

Authors:  Simona Bolamperti; Michela Signo; Alice Spinello; GianLuigi Moro; Gianfranco Fraschini; Francesca Guidobono; Alessandro Rubinacci; Isabella Villa
Journal:  Bone       Date:  2018-04-22       Impact factor: 4.398

8.  The basic route of the nuclear translocation porcine growth hormone (GH)-growth hormone receptor (GHR) complex (pGH/GHR) in porcine hepatocytes.

Authors:  Lan Hainan; Liu Huilin; Muhammad Akram Khan; Zheng Xin; Yang YuJiang; Zhang Hui; Yao Naiquan
Journal:  Gen Comp Endocrinol       Date:  2018-06-08       Impact factor: 2.822

9.  Theranostic combinatorial drug-loaded coated cubosomes for enhanced targeting and efficacy against cancer cells.

Authors:  Leilei Zhang; Jinlong Li; Dan Tian; Lihua Sun; Xu Wang; Miao Tian
Journal:  Cell Death Dis       Date:  2020-01-02       Impact factor: 8.469

Review 10.  The Role of Growth Hormone in Mesenchymal Stem Cell Commitment.

Authors:  Simona Bolamperti; Francesca Guidobono; Alessandro Rubinacci; Isabella Villa
Journal:  Int J Mol Sci       Date:  2019-10-23       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.